NeoPharm CO. LTD (092730) - Total Liabilities
Based on the latest financial reports, NeoPharm CO. LTD (092730) has total liabilities worth ₩18.97 Billion KRW (≈ $12.86 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore NeoPharm CO. LTD annual equity growth to track the company's year-over-year net asset growth rate.
NeoPharm CO. LTD - Total Liabilities Trend (2012–2024)
This chart illustrates how NeoPharm CO. LTD's total liabilities have evolved over time, based on quarterly financial data. See 092730 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
NeoPharm CO. LTD Competitors by Total Liabilities
The table below lists competitors of NeoPharm CO. LTD ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Active Biotech AB
ST:ACTI
|
Sweden | Skr12.50 Million |
|
Woongjin Co Ltd
KO:016880
|
Korea | ₩4.82 Trillion |
|
Havila Kystruten AS
OL:HKY
|
Norway | Nkr5.88 Billion |
|
Synchronoss Technologies Inc
NASDAQ:SNCR
|
USA | $222.87 Million |
|
Vivani Medical Inc.
NASDAQ:VANI
|
USA | $23.66 Million |
|
Xtract One Technologies Inc.
TO:XTRA
|
Canada | CA$12.77 Million |
|
SA Catana Group
PA:CATG
|
France | €126.23 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down NeoPharm CO. LTD's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is NeoPharm CO. LTD worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.36 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NeoPharm CO. LTD's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NeoPharm CO. LTD (2012–2024)
The table below shows the annual total liabilities of NeoPharm CO. LTD from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩15.56 Billion ≈ $10.54 Million |
-10.77% |
| 2023-12-31 | ₩17.43 Billion ≈ $11.81 Million |
+32.70% |
| 2022-12-31 | ₩13.14 Billion ≈ $8.90 Million |
+0.26% |
| 2021-12-31 | ₩13.10 Billion ≈ $8.88 Million |
-14.14% |
| 2020-12-31 | ₩15.26 Billion ≈ $10.34 Million |
-10.49% |
| 2019-12-31 | ₩17.05 Billion ≈ $11.55 Million |
+24.98% |
| 2018-12-31 | ₩13.64 Billion ≈ $9.24 Million |
+49.69% |
| 2017-12-31 | ₩9.11 Billion ≈ $6.18 Million |
+14.80% |
| 2016-12-31 | ₩7.94 Billion ≈ $5.38 Million |
+1.96% |
| 2015-12-31 | ₩7.79 Billion ≈ $5.28 Million |
+84.58% |
| 2012-12-31 | ₩4.22 Billion ≈ $2.86 Million |
-- |
About NeoPharm CO. LTD
NeoPharm CO., LTD. manufactures and sells skin care products in South Korea. The company offers Atopalm, a non-steroid product for sensitive and dry skin; skin dermo-cosmetic products under the Real Barrier brand; products for sensitive, dry, oily, or trouble-prone skin under the ZEROID brand; body moisturizers under the Derma-B brand; and sport care products for athletes under the MISSION ATHELE… Read more